WO1996027008A3 - Mittel zur therapie von tumoren und anderen hyperplasien - Google Patents
Mittel zur therapie von tumoren und anderen hyperplasien Download PDFInfo
- Publication number
- WO1996027008A3 WO1996027008A3 PCT/DE1996/000351 DE9600351W WO9627008A3 WO 1996027008 A3 WO1996027008 A3 WO 1996027008A3 DE 9600351 W DE9600351 W DE 9600351W WO 9627008 A3 WO9627008 A3 WO 9627008A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- hyperplasia
- treating tumours
- tumour suppressor
- tumours
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8525959A JPH10512155A (ja) | 1995-02-28 | 1996-02-26 | 癌およびその他の過形成を治療する薬剤 |
EP96903923A EP0812355A2 (de) | 1995-02-28 | 1996-02-26 | Mittel zur therapie von tumoren und anderen hyperplasien |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19508734 | 1995-02-28 | ||
DE19508734.8 | 1995-02-28 | ||
DE19539130A DE19539130C2 (de) | 1995-02-28 | 1995-10-20 | Mittel zur Therapie von Tumoren und anderen Hyperplasien |
DE19539130.6 | 1995-10-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996027008A2 WO1996027008A2 (de) | 1996-09-06 |
WO1996027008A3 true WO1996027008A3 (de) | 1996-11-14 |
Family
ID=26013265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1996/000351 WO1996027008A2 (de) | 1995-02-28 | 1996-02-26 | Mittel zur therapie von tumoren und anderen hyperplasien |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0812355A2 (de) |
JP (1) | JPH10512155A (de) |
WO (1) | WO1996027008A2 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
ES2527412T3 (es) | 2007-02-15 | 2015-01-23 | Mannkind Corporation | Método para aumentar la respuesta de los linfocitos T |
AU2010310468A1 (en) | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020691A1 (en) * | 1992-04-20 | 1993-10-28 | Tykocinski Mark L | Method for inducing tumor immunity |
WO1995028483A1 (en) * | 1994-04-14 | 1995-10-26 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
WO1996003875A1 (en) * | 1994-07-29 | 1996-02-15 | Emory University | Compositions for targeting materials to cells containing androgen receptors |
WO1996015245A1 (en) * | 1994-11-11 | 1996-05-23 | Arch Development Corporation | A process of inhibiting non-neoplastic pathological cell proliferation |
-
1996
- 1996-02-26 EP EP96903923A patent/EP0812355A2/de not_active Withdrawn
- 1996-02-26 JP JP8525959A patent/JPH10512155A/ja active Pending
- 1996-02-26 WO PCT/DE1996/000351 patent/WO1996027008A2/de not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020691A1 (en) * | 1992-04-20 | 1993-10-28 | Tykocinski Mark L | Method for inducing tumor immunity |
WO1995028483A1 (en) * | 1994-04-14 | 1995-10-26 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
WO1996003875A1 (en) * | 1994-07-29 | 1996-02-15 | Emory University | Compositions for targeting materials to cells containing androgen receptors |
WO1996015245A1 (en) * | 1994-11-11 | 1996-05-23 | Arch Development Corporation | A process of inhibiting non-neoplastic pathological cell proliferation |
Non-Patent Citations (8)
Title |
---|
BACCHETTI, S. & GRAHAM, F.: "Inhibition of cell proliferation by an adenovirus vector expressing human wild type p53 protein", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 3, no. 5, November 1993 (1993-11-01), pages 781 - 788, XP000576129 * |
HANNON, G. & BEACH, D.: "p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest", NATURE, vol. 371, 15 September 1994 (1994-09-15), LONDON GB, pages 257 - 261, XP002008793 * |
LUKAS, J. ET AL.: "Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.", NATURE, (1995 JUN 8) 375 (6531) 503-6, XP002008796 * |
PARRY, D. ET AL.: "Lack of cyclin D-Cdk complexes in Rb -negative cells correlates with high levels of p16INK4 / MTS1 tumour suppressor gene product.", EMBO JOURNAL, (1995 FEB 1) 14 (3) 503-11., XP002008797 * |
SERRANO, M. ET AL.: "A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4", NATURE, vol. 366, 16 December 1993 (1993-12-16), LONDON GB, pages 704 - 707, XP002008795 * |
SHAPIRO, G. ET AL.: "Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.", CANCER RESEARCH, (1995 FEB 1) 55 (3) 505-9., XP002008798 * |
SLEBOS, R. ET AL.: "p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, June 1994 (1994-06-01), WASHINGTON US, pages 5320 - 5324, XP002008794 * |
SPILLARE, E. ET AL.: "Suppression of growth in vitro and tumorigenicity in vivo of human carcinoma cell lines by transfected p16-INK4.", MOLECULAR CARCINOGENESIS 16 (1). 1996. 53-60, XP000576136 * |
Also Published As
Publication number | Publication date |
---|---|
JPH10512155A (ja) | 1998-11-24 |
WO1996027008A2 (de) | 1996-09-06 |
EP0812355A2 (de) | 1997-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3847997A (en) | Inhibitors of the interaction between P53 and MDM2 | |
GEP20043363B (en) | Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation | |
WO2004049918A3 (en) | A system for administering a combination of therapies to a body lumen | |
EE200000466A (et) | Omeprasooli mikrograanulid, nende valmistamismeetod ja farmatseutilised preparaadid | |
IL187254A (en) | ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB | |
IL111734A0 (en) | Compositions for the preparation of in vivo therapeutic products | |
AU6257798A (en) | Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase | |
ZA956263B (en) | Intracellular expression of carboxypeptidase G2 in enzymeprodrug therapy | |
WO2000018331A3 (en) | Drug delivery systems | |
PL308142A1 (en) | Derivatives of 2-amino-4phenyl-4-oxobutyric acids as kynureninase and/or kynurenic 3-hydroxylase inhibitors | |
WO1998048027A3 (en) | Materials and methods for treatment of retinal diseases | |
NZ504928A (en) | Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases | |
WO1996027008A3 (de) | Mittel zur therapie von tumoren und anderen hyperplasien | |
PL346246A1 (en) | Modulating multiple lineage kinase proteins | |
WO2000032765A3 (en) | Ribozyme therapy for the treatment and/or prevention of restenosis | |
GR3020355T3 (en) | Aminosulfonyl urea acat inhibitors | |
MXPA02010759A (es) | Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa. | |
WO2001029226A3 (en) | Apoptosis inducing proteinaceous substance | |
PT871467E (pt) | Formulacao para a libertacao de peptido | |
ZA97596B (en) | Solid instant-release forms of administration and processes for their production | |
MX9707808A (es) | Una composicion farmaceutica que contiene n-clorofenilcarbamatos y n-clorofiniltiocarbamatos para inhibir el crecimiento de virus y canceres. | |
WO2002028874A3 (en) | Tumor proliferation inhibitors | |
WO2002014536A3 (en) | Odulating multiple lineage kinase proteins | |
Novikov et al. | Molecular mechanisms of biological action of low magnetic fields. I. Stability of chromatin from Ehrlich ascite carcinoma and mouse brain cells to the treatment of DNase 1 under combined action of low constant and alternating low-frequency magnetic fields adjusted to the cyclotron resonance of ions of polar amino acids | |
AU6627298A (en) | Product containing idazoxan and 1-dopa as combined pharmaceutical preparation useful for treating parkinson disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996903923 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996903923 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996903923 Country of ref document: EP |